Benjamin Graham Detailed Fundamental Analysis

Validea's guru fundamental report indicates Regeneron Pharmaceuticals (REGN) scores 71% using the Benjamin Graham Value Investor model, which prioritizes low P/B and P/E ratios, low debt, and strong long-term earnings growth. While REGN passes several fundamental tests including long-term EPS growth and debt metrics, it notably fails the P/E and Price/Book ratio criteria, placing it below the 80% threshold typically indicating 'some interest' for this deep value strategy.

Analysis

Regeneron Pharmaceuticals (REGN) presents a conflicting profile when assessed against Validea's Benjamin Graham-based deep value model, scoring a moderate 71%, which falls below the 80% threshold typically indicating strategic interest. The company exhibits significant fundamental strengths, passing criteria for its sales, current ratio, and long-term EPS growth. Furthermore, its balance sheet appears robust, meeting the test for low long-term debt in relation to net current assets. However, the analysis identifies a critical divergence from the value framework in its valuation metrics. REGN fails on both Price-to-Earnings (P/E) and Price-to-Book (P/B) ratio tests, suggesting its current market price is too high to meet the stringent margin of safety required by this deep value philosophy. This creates a classic dichotomy where the company's strong growth and operational health, characteristic of a large-cap biotech firm, are offset by a valuation that is unappealing to a pure value-driven screening process.

Key Decisions for Investors

• Deep value investors following Graham-like principles should view REGN with caution, as its failure on key P/E and P/B valuation metrics makes it an unsuitable candidate for a strict value strategy at its current price.
• Growth-oriented investors may find the positive signals on long-term EPS growth and balance sheet health to be compelling, but must be comfortable with a premium valuation that places the stock outside of traditional value territory.
• Investors should assess if REGN's profile as a fundamentally sound but richly valued growth company aligns with their portfolio's style, and could monitor the stock for significant price pullbacks that might improve its value proposition.